https://www.thebodypro.com/collection/caring-newly-diagnosed-hiv

Featured

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review Img

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review

Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.

Why Nurses Should Take the HIV Self-Test Img

Why Nurses Should Take the HIV Self-Test

People newly diagnosed with HIV must be able to access treatment and support, which could be improved if guided by people who have been taken the test themselves, researchers found.

PositiveLinks: Mobile Intervention for People With HIV Img

PositiveLinks: Mobile Intervention for People With HIV

Study results of an intervention that includes a custom smartphone app tailored to the needs and preferences of a rural population of people with HIV living in the southern U.S.

Doravirine Sets a New Standard for NNRTIs -- but What Role in HIV Treatment Today? Img

Doravirine Sets a New Standard for NNRTIs -- but What Role in HIV Treatment Today?

"Since this appears to be a 'best in class' drug, doravirine has enough advantages that it is a useful advance in HIV therapy, if not a transformational one," writes Paul Sax, M.D.

FDA Approves Doravirine (Pifeltro) and New FDC With TDF/3TC (Delstrigo) in the U.S. Img

FDA Approves Doravirine (Pifeltro) and New FDC With TDF/3TC (Delstrigo) in the U.S.

On Aug. 30, 2018, the U.S. FDA approved doravirine as a separate formulation for use with ART and in a fixed-dose combination with generic tenofovir DF and lamivudine (3TC).

More People With HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study Shows Img

More People With HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study Shows

After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.

ARVs and Children: New Research Shows the Devastating Impact of a Late Start Img
Children (Ages 0-17)

ARVs and Children: New Research Shows the Devastating Impact of a Late Start

The first global comparison of adolescents who acquired HIV as newborns highlights the challenges around treatment for children in developing countries.

Symtuza: FDA Approves New Fixed-Dose Combination for Treatment of HIV Img
News

Symtuza: FDA Approves New Fixed-Dose Combination for Treatment of HIV

On July 17, 2018 the U.S. Food and Drug Administration approved Symtuza, a four-drug combination indicated as a complete regimen for the treatment of HIV-1 infection in adults.

The DMV Balenciaga House Meeting
Features

Study Shows Depressive Symptoms Associated With Detectable HIV Viral Load, but Not With Missed Visits

Adherence to HIV care visits was associated more with mental health conditions before starting antiretroviral treatment than with recent depressive symptoms, while a detectable viral load was related to such symptoms.

Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best Img
News

Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best

On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.